Arax Advisory Partners
CRVO icon

Arax Advisory Partners’s CervoMed CRVO Stock Holding History

Arax Advisory Partners’s Portfolio CRVO Stock Details CRVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53 Buy
17
+3
+21% +$11 ﹤0.01% 5161
2026
Q1 		$20 Buy
14
+9
+180% +$47 ﹤0.01% 3717
2025
Q4 		$40 Sell
5
-27
-84% -$217 ﹤0.01% 3955
2025
Q3 		$258 Buy
+32
New +$275 ﹤0.01% 3430

Other funds holding CRVO

Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BAM
Byrne Asset Management Kingston, New Jersey $179M AUM 29.67% 1-Year Est. Return
Citizens Financial Group
Citizens Financial Group Providence, Rhode Island $8.3B AUM 27.66% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
TDC
Thompson Davis & Co Richmond, Virginia $167M AUM 33.45% 1-Year Est. Return

Arax Advisory Partners's CRVO Position: Q2 2026 in Review

Arax Advisory Partners increased its CervoMed (CRVO) stake by 21% in Q2 2026, buying an estimated $11 and bringing the position to 17 shares worth $53. The position accounts for ﹤0.01% of the portfolio, ranked #5161.

Arax Advisory Partners first reported a position in CRVO in Q3 2025 and has held it in 4 quarters since. The position peaked at $258 in Q3 2025. 37 funds tracked by Wall St. Rank hold CRVO as of Q2 2026.

  • Arax Advisory Partners held 17 shares of CervoMed worth $53 as of Q2 2026.
  • Arax Advisory Partners bought 3 CervoMed shares in Q2 2026, an estimated $11.
  • CervoMed made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #5161 holding.
  • Arax Advisory Partners first reported a position in CervoMed in Q3 2025 and has held it in 4 quarters since.
  • Arax Advisory Partners's CervoMed position peaked at $258 in Q3 2025.
  • 37 funds tracked by Wall St. Rank held CervoMed as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.